​The Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence provide a framework for clinical decision making by clinicians and consumers in a range of service settings involved in the delivery of treatment with long acting depot buprenorphine products.
The guidelines were developed by Professors Nicholas Lintzeris and Adrian Dunlop, and Debbie Masters, based on the available evidence and experience from clinical trials.
The guidelines are intended to be updated in the future to reflect the experiences of clinicians and patients using depot buprenorphine.
The guidelines should be read in conjunction with the NSW Clinical Guidelines: Treatment of Opioid Dependence.
File Size: 673 kb
Type: Guideline
Date of Publication: 12 September 2019
ISBN: 978-1-76081-226-3
SHPN: (CPH) 190431